Years ago Geron had a joint venture with Merck, who acquired three million shares at $9.00/share.
Believe the trials were stopped as ineffective. Today release shows studies stopped by independent
monitoring committee. Is this going to be fast track? Would IMet fall into the same category?
Is Geron technology shared with Merck involved in their success? If so, would a third party buy out
of Geron produce royalties we shareholders are not aware of? FYI